Cyclic amplification of protein misfolding and aggregation

Methods in Molecular Biology

Volumn 299, Issue , 2005, Pages 53-65

  Saá, Paula ^a   Castilla, Joaquín ^a   Soto, Claudio ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Alzheimer's disease; Amyloid; Bovine spongiform encephalopathy; Creutzfeldt Jakob disease; Prion; Protein conformational disorders; Protein misfolding cyclic amplification (PMCA); Scrapie

Indexed keywords

GENE AMPLIFICATION; POLYMERASE CHAIN REACTION; PRION DISEASE; PROTEIN AGGREGATION; PROTEIN MISFOLDING; PROTEIN MISFOLDING CYCLIC AMPLIFICATION;

EID: 22844434827     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1385/1-59259-874-9:053     Document Type: Chapter

References (52)

1. Soto, C. (2003) Unfolding the role of protein misfolding in neurodegenerative diseases. Nature Rev. Neurosci. 4, 49-60.
2. Soto, C. (2001) Protein misfolding and disease; protein refolding and therapy. FEBS Lett. 498, 204-207.
3. Dobson, C. M. (1999) Protein misfolding, evolution and disease. Trends Biochem. Sci. 24, 329-332.
4. Carrell, R. W. and Lomas, D. A. (1997) Conformational disease. Lancet 350, 134-138.
5. Kelly, J. W. (1996) Alternative conformations of amyloidogenic proteins govern their behavior. Curr. Opin. Struct. Biol. 6, 11-17.
6. Soto, C. and Saborio, G. P. (2001) Prions: disease propagation and disease therapy by conformational transmission. Trends Mol. Med. 7, 109-114.
7. Prusiner, S. B. (1991) Molecular biology of prion diseases. Science 252, 1515-1522.
8. Roos, R., Gajdusek, D. C., and Gibbs, C. J. Jr. (1973) The clinical characteristics of transmissible Creutzfeldt-Jakob disease. Brain 96, 1-20.
9. Will, R. G., Ironside, J. W., Zeidler, M., et al. (1996) A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347, 921-925.
10. Cousens, S. N., Vynnycky, E., Zeidler, M., Will, R. G., and Smith, P. G. (1997) Predicting the CJD epidemic in humans. Nature 385, 197-198.
11. Bruce, M. E., Will, R. G., Ironside, J. W., et al. (1997) Transmissions to mice indicate that 'new variant CJD is caused by the BSE agent. Nature 389, 498-501.
12. Soto, C. and Castilla, J. (2004) The controversial protein-only hypothesis of prion propagation. Nat. Med. 10Suppl, S63-S67.
13. Prusiner, S. B. (1998) Prions. Proc. Natl. Acad. Sci. USA 95, 13363-13383.
14. Pan, K. M., Baldwin, M., Nguyen, J., et al. (1993) Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc. Natl. Acad. Sci. USA 90, 10962-10966.
15. Cohen, F. E. and Prusiner, S. B. (1998) Pathologic conformations of prion proteins. Annu. Rev. Biochem. 67, 793-819.
16. Baldwin, M. A., Cohen, F. E., and Prusiner, S. B. (1995) Prion protein isoforms, a convergence of biological and structural investigations. J. Biol. Chem. 270, 19197-19200.
17. Bueler, H., Aguzzi, A., Sailer, A., Greiner, R. A., Autenried, P., Aguet, M., and Weissmann, C. (1993) Mice devoid of PrP are resistant to scrapie. Cell 73, 1339-1347.
18. DeArmond, S. J. and Prusiner, S. B. (1995) Prion protein transgenes and the neuropathology in prion diseases. Brain Pathol. 5, 77-89.
19. Kocisko, D. A., Come, J. H., Priola, S. A., et al. (1994) Cell-free formation of protease-resistant prion protein. Nature 370, 471-474.
20. Lucassen, R., Nishina, K., and Supattapone, S. (2003) In vitro amplification of protease-resistant prion protein requires free sulfhydryl groups. Biochemistry 42, 4127-4135.
21. Saborio, G. P., Permanne, B., and Soto, C. (2001) Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 411, 810-813.
22. Deleault, N. R., Lucassen, R. W., and Supattapone, S. (2003) RNA molecules stimulate prion protein conversion. Nature 425, 717-720.
23. Cohen, F. E. (1999) Protein misfolding and prion diseases. J. Mol. Biol. 293, 313-320.
24. Jarrett, J. T. and Lansbury, P. T. Jr. (1993) Seeding “one-dimensional crystallization” of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73, 1055-1058.
25. Harper, J.D. and Lansbury, P. T. Jr. (1997) Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 66, 385-407.
26. Masel, J., Jansen, V. A., and Nowak, M. A. (1999) Quantifying the kinetic parameters of prion replication. Biophys. Chem. 77, 139-152.
27. Caughey, B., Kocisko, D. A., Raymond, G. J., and Lansbury, P. T. Jr. (1995) Aggregates of scrapie-associated prion protein induce the cell-free conversion of protease-sensitive prion protein to the protease-resistant state. Chem. Biol. 2, 807-817.
28. Masel, J. and Jansen, V. A. (2001) The measured level of prion infectivity varies in a predictable way according to the aggregation state of the infectious agent. Biochim. Biophys. Acta 1535, 164-173.
29. Prusiner, S. B., McKinley, M. P., Bowman, K. A., et al. (1983) Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 35, 349-358.
30. Jeffrey, M., Goodbrand, I. A., and Goodsir, C. M. (1995) Pathology of the transmissible spongiform encephalopathies with special emphasis on ultrastructure. Micron. 26, 277-298.
31. Soto, C., Saborio, G. P., and Anderes, L. (2002) Cyclic amplification of protein misfolding: application to prion-related disorders and beyond. Trends Neurosci. 25, 390-394.
32. Bessen, R. A., Raymond, G. J., and Caughey, B. (1997) In situ formation of protease-resistant prion protein in transmissible spongiform encephalopathy-infected brain slices. J. Biol. Chem. 272, 15227-15231.
33. Horiuchi, M. and Caughey, B. (1999) Prion protein interconversions and the transmissible spongiform encephalopathies. Structure Fold. Des. 7, R231-R240.
34. Kocisko, D. A., Priola, S. A., Raymond, G. J., Chesebro, B., Lansbury, P. T. Jr., and Caughey, B. (1995) Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. Proc. Natl. Acad. Sci. USA 92, 3923-3927.
35. Chabry, J., Caughey, B., and Chesebro, B. (1998) Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. J. Biol. Chem. 273, 13203-13207.
36. Caughey, B., Raymond, G. J., and Bessen, R. A. (1998) Strain-dependent differences in beta-sheet conformations of abnormal prion protein. J. Biol. Chem. 273, 32230-32235.
37. Aguzzi, A. and Weissmann, C. (1997) Prion research: the next frontiers. Nature 389, 795-798.
38. Weber, T., Otto, M., Bodemer, M., and Zerr, I. (1997) Diagnosis of Creutzfeldt-Jakob disease and related human spongiform encephalopathies. Biomed. Pharmacother. 51, 381-387.
39. Steinhoff, B. J., Racker, S., Herrendorf, G., et al. (1996) Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease. Arch. Neurol. 53, 162-166.
40. Budka, H., Aguzzi, A., Brown, P., et al. (1995) Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol. 5,459-466.
41. Collinge, J. (2001) Prion diseases of humans and animals: their causes and molecular basis. Annu. Rev. Neurosci. 24, 519-550.
42. Frosh, A., Joyce, R., and Johnson, A. (2001) Iatrogenic vCJD from surgical instruments. BMJ 322, 1558-1559.
43. Soto, C. (2004) Diagnosing prion diseases: needs, challenges, and hopes. Nature Rev. Microbiol., in press.
44. Schiermeier, Q. (2001) Testing times for BSE. Nature 409, 658-659.
45. Anonymous (2001) Scientists race to develop a blood test for vCJD. Nat. Med. 7, 261.
46. Ingrosso, L., Vetrugno, V., Cardone, F., and Pocchiari, M. (2002) Molecular diagnostics of transmissible spongiform encephalopathies. Trends Mol. Med. 8,273-280.
47. Aguzzi, A. (2000) Prion diseases, blood and the immune system: concerns and reality. Haematologica 85, 3-10.
48. Brown, P., Cervenakova, L., and Diringer, H. (2001) Blood infectivity and the prospects for a diagnostic screening test in Creutzfeldt-Jakob disease. J. Lab. Clin. Med. 137,5-13.
49. Wadsworth, J. D., Joiner, S., Hill, A. F., et al. (2001) Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 358, 171-180.
50. Carrell, R. W. and Lomas, D. A. (1997) Conformational disease. Lancet 350, 134-138.
51. Lomakin, A., Chung, D. S., Benedek, G. B., Kirschner, D. A., and Teplow, D. B. (1996) On the nucleation and growth of amyloid beta-protein fibrils: detection of nuclei and quantitation of rate constants. Proc. Natl. Acad. Sci. USA 93, 1125-1129.
52. Teplow, D. B. (1998) Structural and kinetic features of amyloid beta-protein fibrillogenesis. Amyloid 5, 121-142.